Nasdaq: KPTI

Karyopharm Therapeutics, Inc.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Its scientific expertise is focused on the understanding of the regulation of intracellular transport between the nucleus and the cytoplasm. Karyopharm has discovered and developed novel, small molecule, Selective Inhibitors of Nuclear Export, or SINE, compounds that inhibit the nuclear export protein XPO1.